Skip to content
Neuronet
Neuronet - The support action for EU research on neurodegeneration
  • ABOUT
        • Objectives
        • Glossary
        • Work Packages
        • Partners
        • Executive Committee
        • Task Forces
        • Working Groups
        • Scientific Coordination Board
  • EVENTS
        • 2021: Virtual event
        • 2020: Virtual Event
        • 2019: The Hague
        • Event Calendar
  • NEWS
        • Latest news
        • Neuronet newsletters
        • Neuronet in the Media
  • PROJECTS
        • Ongoing Projects
        • Completed Projects
        • Project Overview
        • Project Timescales
  • RESOURCES
        • Asset Map
        • Project Tools
        • Regulatory & HTA Decision Tool
        • Neuronet Tools
        • Neuronet Deliverables
        • Neuronet Presentations
        • Publications
        • Useful resources for young researchers
  • KNOWLEDGE BASE

AMYPAD

AMYPAD Post-Doc Merle Hoenig presents at SNMMI confrerence

28th June 2022
AMYPAD logo

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting is recognised as the

AMYPAD announces end of recruitment in the Prognostic and Natural History Study

17th May 2022
AMYPAD logo

On 11 May, the members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project

AMYPAD hosts a disclosure biomarker symposium

30th May 202230th April 2022
AMYPAD logo

On 1 April, the Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project held an online

New partnership between AMYPAD and ADDI powers global open access to Alzheimer’s disease imaging data

19th April 2022
AMYPAD logo

A common sign of Alzheimer’s disease are deposits of a protein called beta amyloid. The

Neuronet convenes 8th meeting of its Scientific Coordination Board

1st April 20221st April 2022

On 30 March, the Innovative Medicines Initiative (IMI) funded Neuronet Coordination and Support Action convened

Neuronet publishes series of project introduction videos during Brain Awareness Week

20th April 202214th March 2022

The Neuronet programme launched a series of short introduction videos of the various Innovative Medicines

New partnership between AMYPAD and ADDI powers global open access to project’s data

23rd February 2022
AMYPAD logo

The AMYPAD consortium is pleased to announce its collaboration with the Alzheimer’s Disease Data Initiative

AMYPAD project reports on highlights in 2021

8th February 2022
AMYPAD logo

The collaboration within the AMYPAD consortium has been productive and efficient during the fifth year of the

Uncertainty of MR-PET image registration is mainly driven by the quality of PET images

24th November 2021
AMYPAD logo

Accurate regional brain quantitative PET measurements, particularly when using partial volume correction, rely on robust

Quantifying longitudinal & regional changes in Aβ can improve the prediction of cognitive functioning

12th November 202111th November 2021
AMYPAD logo

The value of quantitative longitudinal and regional amyloid beta (Aβ) measurements in predicting cognitive decline

Post navigation
Older posts
Page1 Page2 … Page4 Next →

LATEST NEWS

  • AMYPAD Post-Doc Merle Hoenig presents at SNMMI confrerence

    28th June 2022
    The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting is recognised as theRead More
  • NEW VIDEO: The Mobilise-D Journey!

    28th June 2022
    The Mobilise-D consortium are three-and-a-half years into the project, and what a journey they haveRead More
  • Alzheimer Europe launches Anti-Stigma Award

    27th June 2022
    On 22 June, Alzheimer Europe launched its Anti-Stigma Award. The award recognises an outstanding initiativeRead More
  • Mobilise-D Workshop at the International Conference on Ambulatory Monitoring of Physical Activity and Movement (ICAMPAM)

    17th June 2022
    Workshop – Validating digital mobility tools: the Mobilise-D experience Real-world monitoring of mobility and functionRead More
  • IDEA-FAST Meeting on the Clinical Observational Study in Kiel, May 2022

    13th June 2022
    On May 30 and 31, members of IDEA-FAST met in Kiel, Germany, to prepare forRead More

Neuronet

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any information on this website solely reflects the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

 

 

Innovative Medicines InitiativeEU Flag logoEuropean Federation of Pharmaceutical Industries and Associations logoParksinson's UK logo

Disclaimer
About IMI
Legal notice
Privacy policy

@ 2019 – IMI-NEURONET

© 2022 - IMI-NEURONET
We use cookies to offer you a better browsing experience and to analyze site traffic. Read about how we use cookies and how you can control them in our Cookie Policy. If you continue to use this site, you consent to our use of cookies. AcceptCookie policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT